{
"id":"mk19_a_gm_t65",
"number":65,
"bookId":"gm",
"title":{
"__html":"Mechanisms of Pharmacogenomic Variants"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"b2619c",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 65. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_gm_t65"
}
]
},
"Mechanisms of Pharmacogenomic Variants"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7a3d46",
"class":"col hd l",
"children":[
"Mechanism"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5db77f",
"class":"col hd l",
"children":[
"Drug"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ef9730",
"class":"col hd l",
"children":[
"Associated Gene"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"4"
},
"children":[
" ",
{
"type":"p",
"hlId":"8482d9",
"class":"col hd l",
"children":[
"Pharmacokinetic"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"692e64",
"class":"cell txt l",
"children":[
"Altered metabolism of active compound"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3b3194",
"class":"cell txt l",
"children":[
"Pantoprazole; other proton pump inhibitors to a lesser extent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"32531f",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"CYP2C19"
]
},
" "
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7c6347",
"class":"cell txt l",
"children":[
"Ultrarapid metabolizers of CYP2C19 deactivate pantoprazole quickly, leading to reduced efficacy at standard doses"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"62a392",
"class":"cell txt l",
"children":[
"Altered metabolism of prodrug"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9608dd",
"class":"cell txt l",
"children":[
"Codeine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f37271",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"CYP2D6"
]
},
" "
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"49f67c",
"class":"cell txt l",
"children":[
"Ultrarapid metabolizers of CYP2D6 convert codeine into morphine more quickly, potentially leading to toxicity"
]
},
" ",
{
"type":"p",
"hlId":"8c8ee9",
"class":"cell txt l",
"children":[
"Poor and intermediate metabolizers of CYP2D6 convert codeine into morphine slowly, resulting in attenuated effect"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ece3",
"class":"cell txt l",
"children":[
"Clopidogrel"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"32531f",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"CYP2C19"
]
},
" "
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"47e85d",
"class":"cell txt l",
"children":[
"Poor and intermediate metabolizers of CYP2C19 slowly convert clopidogrel to its active form; the FDA warns of an increased risk for treatment failure in this population"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2acbd1",
"class":"cell txt l",
"children":[
"Altered drug uptake"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0708da",
"class":"cell txt l",
"children":[
"Simvastatin; other statins to a lesser extent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f8505f",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"SLCO1B1"
]
},
" "
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"059c13",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"SLCO1B1"
]
},
" alters hepatic uptake by the OATP1B1 transporter; reduced uptake may increase myopathy risk"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"4"
},
"children":[
" ",
{
"type":"p",
"hlId":"ce23ea",
"class":"col hd l",
"children":[
"Pharmacodynamic"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"037ba2",
"class":"cell txt l",
"children":[
"Altered receptor binding affinity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"00fb95",
"class":"cell txt l",
"children":[
"Warfarin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"289d3a",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"VKORC1"
]
},
" "
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a9d32f",
"class":"cell txt l",
"children":[
"Increased warfarin affinity in certain ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"VKORC1"
]
},
" polymorphisms may indicate that a lower dose of warfarin is needed to achieve a therapeutic INR"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ae75c8",
"class":"cell txt l",
"children":[
"Off-target effects"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3311f2",
"class":"cell txt l",
"children":[
"Sulfa drugs, NSAIDs, quinine, fluoroquinolones"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"20349f",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"G6PD"
]
},
" "
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bbc971",
"class":"cell txt l",
"children":[
"Reduced G6PD activity increases susceptibility to oxidative stress, leading to hemolysis"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"4"
},
"children":[
" ",
{
"type":"p",
"hlId":"825a2f",
"class":"col hd l",
"children":[
"Hypersensitivity"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"422b7f",
"class":"cell txt l",
"children":[
"Non-anaphylactic systemic hypersensitivity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5081e1",
"class":"cell txt l",
"children":[
"Abacavir"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"228b84",
"class":"cell txt l",
"children":[
"HLA-B*57:01"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d450c0",
"class":"cell txt l",
"children":[
"Increased risk for hypersensitivity reaction; the FDA recommends testing before prescribing"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ff2469",
"class":"cell txt l",
"children":[
"Non-anaphylactic cutaneous hypersensitivity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"051b8d",
"class":"cell txt l",
"children":[
"Carbamazepine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4fc171",
"class":"cell txt l",
"children":[
"HLA-B*15:02"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"45af23",
"class":"cell txt l",
"children":[
"Increased risk for STS or TEN; the FDA recommends testing patients of Asian descent before prescribing"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_3-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2e4c04",
"class":"cell txt l",
"children":[
"Allopurinol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"312795",
"class":"cell txt l",
"children":[
"HLA-B*58:01"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"05f158",
"class":"cell txt l",
"children":[
"Increased risk for severe cutaneous adverse reactions (i.e., STS or TEN); the American College of Rheumatology conditionally recommends testing patients of Southeast Asian (e.g., Han Chinese, Korean, Thai) descent and African American patients before prescribing"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CYP2C19 = cytochrome P450 2C19; CYP2D6 = cytochrome P450 2D6; G6PD = glucose-6-phosphate dehydrogenase; OATP1B1 = organic anion transporting protein B1; SLCO1B1 = solute carrier organic anion transporter family member 1B1; STS = Stevens-Johnson syndrome; TEN = toxic epidermal necrolysis; VKORC1 = vitamin K 2,3-epoxide reductase complex subunit 1."
]
]
}